Anna K. Winge-Main

  • Consultant, PhD student; MD
  • +47 22 78 11 62

HELSE SØR ØST

Education:

  • September 2019 – ongoing: PhD student Dept. of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway
  • December 2013: GMC registered Specialist in Clinical Oncology, UK.
  • April 2011: Specialist in Oncology, Norway
  • 2002: Certified Doctor in Norway
  • 1995 – 2002: Medical studies, Semmelweis University of Medicine, Budapest, Hungary

Research interest/projects:

  • Development of Therapeutic TCR against malignant melanoma
  • (Principal) investigator for several melanoma trials with immunotherapy and targeted therapies
  • General interest in immunotherapy and stereotactic radiation therapy in clinic practice

Work experience:

  • April 2017- ongoing: Clinical Lead oncological melanoma treatment, Oslo University Hospital, Department of Oncology
  • August 2014 – ongoing: Consultant for melanoma, Oslo University Hospital, Department of Oncology
  • 2010 – May 2011: Locum Consultant urooncology, Oslo University Hospital, Department of Oncology
  • 2009 – okt.2010: Junior Doctor, Oslo University Hospital, Department of Oncology
  • 2005 – Sept 2008: Junior Doctor, Oslo University Hospital, Department of Oncology
  • 2004 – July 2005: Junior Doctor, Ringerike Hospital, Department of Internal Medicine, Hønefoss, Norway
  • 2004 – Aug. 2004: Inter Doctor, General Medical Practice, Torget Legesenter, Askim, Norway
  • 2003 – Jan. 2004: Intern Doctor, Sykehuset i Øsfold, Department of Internal Medicine and Department of Surgery, Fredrikstad, Norway
  • 2002 – Dec. 2002: Locum Junior Doctor, Ringerike Hospital, Department of Internal Medicine, Hønefoss, Norway
 

Publications 2024

Reis Costa D, Winge-Main AK, Skog A, Tsuruda KM, Robsahm TE, Kulle Andreassen B (2024)
From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway
Acta Oncol, 63, 965-973
DOI 10.2340/1651-226X.2024.41266, PubMed 39690735

Publications 2023

Winge-Main A, Robsahm TE, Nyakas M, Festervoll G, Torkilseng E, Thybo S, Pati S, Carroll R (2023)
Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway
Future Oncol, 19 (3), 205-215
DOI 10.2217/fon-2022-0969, PubMed 36974621

Publications 2022

Berentzen Å, Brevig T, Hermann R, Ryder T, Winge-Main AK (2022)
Melanoma - investigation and primary treatment
Tidsskr Nor Laegeforen, 142 (15)
DOI 10.4045/tidsskr.22.0043, PubMed 36286571

Berentzen Å, Brevig T, Hermann R, Ryder T, Winge-Main AK (2022)
Correction: Melanoma - investigation and primary treatment
Tidsskr Nor Laegeforen, 142 (1)
DOI 10.4045/tidsskr.22.0806, PubMed 36655962

Publications 2021

Heck A, Winge-Main AK (2021)
Silent, isolated ACTH deficiency in malignant melanoma patients treated with immune checkpoint inhibitors
BMJ Case Rep, 14 (5)
DOI 10.1136/bcr-2021-241981, PubMed 34045201

Publications 2020

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther, 29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

Winge-Main AK, Wälchli S, Inderberg EM (2020)
T cell receptor therapy against melanoma-Immunotherapy for the future?
Scand J Immunol, 92 (4), e12927
DOI 10.1111/sji.12927, PubMed 32640053

Publications 2010

Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fosså SD, Lilleby W (2010)
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma
Clin Oncol (R Coll Radiol), 23 (5), 339-43
DOI 10.1016/j.clon.2010.11.006, PubMed 21134733

Scroll to top